How Does Lerodalcibep Compare to Other PCSK9 Inhibitors?

July 2026

Rx lerodalcibep (Lerochol) is a new subcutaneous self-injectable med for high cholesterol.

You’ll hear it’s a third generation PCSK9 inhibitor. It works as a small protein that binds to PCSK9 in the blood and blocks its effects.

Alirocumab (Praluent) and evolocumab (Repatha) are monoclonal antibodies that bind to PCSK9...and inclisiran (Leqvio) is a small interfering RNA that prevents formation of the PCSK9 protein in the liver.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote